All In Biotech

Drug Trial Radar · NCT07699380

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Breakthrough T1D
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center/Diabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.

Conditions

  • Type 1 Diabetes (T1D)
  • Metabolic Diseases
  • Glucose Metabolism Disorders
  • Endocrine System Diseases
  • Autoimmune Diseases
  • Immune System Diseases
  • Diabetes Melletus, Type 1
  • Nutritional and Metabolic Diseases
  • Combination Therapy

Interventions

  • AMX0035Drug

    AMX0035 sachets

  • PlaceboDrug

    Placebo sachets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in whole-body insulin sensitivity (M-value) measured by hyperinsulinemic-euglycemic clampTime frame: Baseline, 24 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Washington Medicine Diabetes Institute (UWMDI)

    Seattle, Washington · Recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.